Polyrizon Announces U.S. Patent Publication for Trap & Target Nasal Drug Delivery Platform
On June 17, 2026, Polyrizon Ltd. (Nasdaq: PLRZ) announced the publication of U.S. patent application No. US 2024/0358741 A1, titled 'Mucoadhesive Polymers for Nasal Drug Delivery.' The application covers the companyβs proprietary Trap & Target (T&T) mucoadhesive polymer technology platform. This platform is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing retention and improving the absorption of active pharmaceutical ingredients (APIs). The technology utilizes biocompatible compositions, including sulfated polysaccharides and hydrophilic polymers, to create a durable film on mucosal surfaces. Polyrizon intends for this platform to support a wide range of therapeutic compounds, including vaccines, biologics, and anti-inflammatory drugs, for both localized and systemic administration. While the T&T technology is currently in the early stages of pre-clinical development, the publication of this patent application marks a step in protecting the company's intellectual property regarding its intranasal hydrogel delivery systems.